Roivant Sciences Ltd. Common Shares (ROIV)
NASDAQ: ROIV · Pharmaceutical Preparations · London,
Our rating: Cautious
Cautious reaffirmed at $41.19, moderate conviction, November 10, 2026.
Breaks if: The cautious call is wrong if Roivant reports quarterly revenue above $50M within the next four quarters — indicating that a pipeline asset has reached meaningful commercial scale — or if the stock sustains above $55 for 20 or more consecutive trading days following a confirmed Phase 3 success or FDA approval that creates a credible near-term revenue stream. Either condition would signal the market correctly priced in pipeline progress that the current financials do not yet reflect.
Key figures
| Market value | $28.0B |
|---|---|
| Revenue, last 12 months | $41M |
| Net income, last 12 months | −$344M |
| Free cash flow, last 12 months | −$33M |
| Price to earnings | n/a |
| Free cash flow yield | −0.1% |
| Dividend yield | 0.0% |
| Operating margin | −1358.1% |
| Return on equity | −8.2% |
| Beta to the S&P 500 | 0.91 |
| Volatility, annualized | 38.7% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | $35M | 2135.6% | $-0.27 | $594M |
| June 30, 2026 | $1M | −33.5% | $-0.26 | −$271M |
| March 31, 2026 | $3M | −66.7% | $0.34 | −$165M |
| December 31, 2025 | $2M | −77.8% | $-0.38 | −$192M |
| September 30, 2025 | $2M | −64.9% | $-0.17 | −$194M |
| June 30, 2025 | $2M | −72.8% | $-0.33 | −$208M |
| March 31, 2025 | $8M | −16.1% | $-0.29 | −$173M |
| December 31, 2024 | $9M | −42.1% | $0.23 | −$209M |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $0.01B: Claude 55%, Gemini 55%, Mistral 40%
- Diluted earnings per share are above zero: Claude 25%, Gemini 25%, Mistral 25%
- Free cash flow for the quarter is above zero: Claude 45%, Gemini 30%, Mistral 20%
14 ledger entries and 21 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.